Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies

NCT07131449 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xinxiang Medical College as lead sponsor.

NCT NCT07131449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07131449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies
Lead sponsor
The First Affiliated Hospital of Xinxiang Medical College
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma